These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29076382)

  • 21. Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.
    Guazzelli A; Bakker E; Tian K; Demonacos C; Krstic-Demonacos M; Mutti L
    Expert Opin Investig Drugs; 2017 Aug; 26(8):933-944. PubMed ID: 28679291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis
    Renz M; Torres R; Dolan PJ; Tam SJ; Tapia JR; Li L; Salmans JR; Barbour RM; Shughrue PJ; Nijjar T; Schenk D; Kinney GG; Zago W
    Amyloid; 2016 Sep; 23(3):168-177. PubMed ID: 27494229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic and therapeutic approach of systemic amyloidosis.
    Hazenberg BP; van Gameren II; Bijzet J; Jager PL; van Rijswijk MH
    Neth J Med; 2004 Apr; 62(4):121-8. PubMed ID: 15255082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical aspects of systemic amyloid diseases.
    Obici L; Perfetti V; Palladini G; Moratti R; Merlini G
    Biochim Biophys Acta; 2005 Nov; 1753(1):11-22. PubMed ID: 16198646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Amyloid light chain amyloidosis].
    Suzuki K; Shimizu T
    Brain Nerve; 2014 Jul; 66(7):795-809. PubMed ID: 24998824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular dynamics simulations and novel drug discovery.
    Liu X; Shi D; Zhou S; Liu H; Liu H; Yao X
    Expert Opin Drug Discov; 2018 Jan; 13(1):23-37. PubMed ID: 29139324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy.
    Cohen AD; Comenzo RL
    Hematology Am Soc Hematol Educ Program; 2010; 2010():287-94. PubMed ID: 21239808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Renal amyloidosis].
    Kościelska M; Shebani Z; Matuszkiewicz-Rowińska J
    Przegl Lek; 2013; 70(4):205-10. PubMed ID: 23991559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
    Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
    Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary amyloidosis in hematological disorders.
    Cordier JF
    Semin Respir Crit Care Med; 2005 Oct; 26(5):502-13. PubMed ID: 16267701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging treatments for amyloidosis.
    Sayed RH; Hawkins PN; Lachmann HJ
    Kidney Int; 2015 Mar; 87(3):516-26. PubMed ID: 25469850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.
    Shum E; Wang F; Kim S; Perez-Soler R; Cheng H
    Expert Opin Investig Drugs; 2017 Apr; 26(4):415-426. PubMed ID: 28277882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New concepts in the treatment and diagnosis of amyloidosis.
    Milani P; Palladini G; Merlini G
    Expert Rev Hematol; 2018 Feb; 11(2):117-127. PubMed ID: 29307226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
    Higaki JN; Chakrabartty A; Galant NJ; Hadley KC; Hammerson B; Nijjar T; Torres R; Tapia JR; Salmans J; Barbour R; Tam SJ; Flanagan K; Zago W; Kinney GG
    Amyloid; 2016 Jun; 23(2):86-97. PubMed ID: 26981744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies.
    Damas AM; Saraiva MJ
    J Struct Biol; 2000 Jun; 130(2-3):290-9. PubMed ID: 10940233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease.
    Anand K; Sabbagh M
    Expert Opin Investig Drugs; 2015; 24(10):1355-60. PubMed ID: 26289787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigational drugs for idiopathic pulmonary fibrosis.
    Varone F; Montemurro G; Macagno F; Calvello M; Conte E; Intini E; Iovene B; Leone PM; Mari PV; Richeldi L
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1019-1031. PubMed ID: 28777013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal amyloidosis in childhood. An overview of the topic with 25 years experience.
    Tinaztepe K
    Turk J Pediatr; 1995; 37(4):357-73. PubMed ID: 8560604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QSAR studies in the discovery of novel type-II diabetic therapies.
    Abuhammad A; Taha MO
    Expert Opin Drug Discov; 2016; 11(2):197-214. PubMed ID: 26558613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Advances in diagnosis and treatment of AL amyloidosis].
    Zelichowski G; Lubas A; Wańkowicz Z
    Pol Merkur Lekarski; 2008 Apr; 24(142):340-5. PubMed ID: 18634370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.